Reporting Season

Why relentless innovation is Pro Medicus’ biggest opportunity and risk

Fri 16 Feb 24, 1:53pm (AEST)


  • Pro Medicus (ASX: PME) has garnered significant market attention in recent years, emerging as a growth stock standout
  • The company's share price has soared from just above $4 in 2017 to a high exceeding $111, despite a recent sharp selloff, reflecting its remarkable growth trajectory alongside record results
  • Co-founder and CEO Dr. Sam Hupert, far from stepping back, remains deeply engaged in the industry, declaring this as the prime time to be involved
  • He sees artificial intelligence as a complementary force in healthcare imaging, capable of elevating standards further
  • In an interview, Hupert discusses recent major contract wins and the future pipeline, as well as the company's approach to collaborating with thought leaders to expand opportunities

Related Tags

Created By

Chris Conway

Fri 16 Feb 24, 1:53pm (AEST)

Get the latest news and insights direct to your inbox

Subscribe free